Abstract: Compounds of formula (I) ##STR1## wherein the substituents are as defined herein, are antiparasitic agents.

Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1##

Abstract: A novel compound having antibacterial activity according to the the formula ##STR1## The compound of the present invention may be prepared from (9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzadiazine-6-carboxylic acid by treatment with an oxidizing agent, such as hydrogen peroxide in the presence of an aqueous inorganic base. Additionally, there are provided methods for treating animals, including humans, suffering from bacterial infections.

Abstract: Compounds of formula (I): ##STR1## or pharmaceutically, veterinarily or agriculturally acceptable salts thereof, or pharmaceutically, veterinarily or agriculturally acceptable solvates of either entity, wherein R.sup.1 is 2,4,6-trisubstituted phenyl or 3,5-disubstituted pyridin-2-yl; R.sup.3 is hydrogen; C.sub.2 to C.sub.5 alkyl substituted with one or more halo and with hydroxy; C.sub.2 to C.sub.5 alkanoyl substituted with one or more halo; C.sub.2 to C.sub.6 alkenyl optionally substituted with one or more halo; halo; amino or CONH.sub.2 ; R.sup.5 is hydrogen, amino or halo; R.sup.2 and R.sup.4 are each independently selected from hydrogen, fluoro, chloro and bromo; R.sup.6 and R.sup.8 are hydrogen; and R.sup.7 is hydrogen or C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo; are parasiticidal agents.

Abstract: Compounds of formula (I): ##STR1## wherein the substituents are as defined herein, are antiparasitic agents.

Abstract: The present invention relates to compounds of formula 1 ##STR1## and to pharmaceutically acceptable salts and solvates thereof, wherein Z, R, R.sup.3 and R.sup.4 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to said mammal.

Abstract: Compounds of formula (I) or pharmaceutically, veterinarily or agriculturally acceptable salts thereof, or pharmaceutically, veterinarily or agriculturally acceptable solvates of either entity, wherein R.sup.1 is 2,4,6-trisubstituted phenyl or 3,5-disubstituted pyridin-2-yl; R.sup.3 is C.sub.1 -C.sub.4 alkyl optionally substituted with hydroxy or with one or more halo; cyano, C.sub.1 to C.sub.5 alkanoyl or phenyl; R.sup.5 is hydrogen, C.sub.1 to C.sub.4 alkyl, amino or halo; R.sup.2 and R.sup.4 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo or, together with the carbon atom to which they are attached, form a C.sub.3 to C.sub.6 cycloalkyl group; R.sup.6 and R.sup.8 are each independently selected from hydrogen, C.sub.1 to C.sub.4 alkyl, fluoro, chloro and bromo; or, when R.sup.2 and R.sup.4 do not form part of a cycloalkyl group, R.sup.2 and R.sup.6, together with the carbon atoms to which they are attached, may form a C.sub.5 to C.sub.

Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene for prophylaxis, diagnostic, and treatment of CCV infections.

Abstract: A compound of the formula: ##STR1## and its pharmaceutically effective salts, wherein R.sup.1 and R.sup.2 are independently selected from the following:(a) hydrogen, halo, R.sup.5 --, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, hydroxy-R.sup.5 --, R.sup.5 --O--R.sup.5 --, or the like; (b) Ar--, Ar--R.sup.5 --, Ar--C.sub.2-6 alkenyl, Ar--C.sub.2-6 alkynyl, Ar--O--, Ar--O--R.sup.5 -- or the like; (c) R.sup.5 --C(O)--, --NO.sub.2, cyano, NH.sub.2 --C(O)--, R.sup.5 --NH--C(O)--, (R.sup.5).sub.2 --N--C(O)--, Ar--C(O)-- or the like; and (d) R.sup.5 --C(O)--NH--, Ar--C(O)--NH-- or the like; wherein Ar is optionally substituted aryl or heteroaryl such as phenyl and pyridyl; and wherein R.sup.5 is optionally halo-substituted C.sub.1-6 alkyl; R.sup.3 is selected from the following: (e) cyano, formyl, tetrazolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, R.sup.5 --C(O)--, C.sub.2-6 alkenyl-C(O)--, C.sub.2-6 alkynyl-C(O)--, R.sup.5 --C(O)--R.sup.5 --, or the like; (f) R.sup.5 --C(O)--NH--, Ar--C(O)--NH--, or the like; (g) R.

Abstract: Compounds of formula (I): ##STR1## or pharmaceutically, veterinarily or agriculturally acceptable salts thereof, or pharmaceutically, veterinarily or agriculturally acceptable solvates of either entity, wherein R.sup.1 is 2,4,6-trisubstituted phenyl or 3,5-disubstituted pyridin-2-yl; R.sup.3 is hydrogen; C.sub.2 to C.sub.5 alkyl substituted with one or more halo and with hydroxy; C.sub.2 to C.sub.5 alkanoyl substituted with one or more halo; C.sub.2 to C.sub.6 alkenyl optionally substituted with one or more halo; halo; amino or CONH.sub.2 ; R.sup.5 is hydrogen, amino or halo; R.sup.2 and R.sup.4 are each independently selected from hydrogen, fluoro, chloro and bromo; R.sup.6 and R.sup.8 are hydrogen; and R.sup.7 is hydrogen or C.sub.1 to C.sub.4 alkyl optionally substituted with one or more halo; are parasiticidal agents.

Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.

Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from ether or ester-linked alkyl groups, and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.

Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active molecules into cells. Typically, the amphiphiles contain lipophilic groups derived from steroids or from mono or dialkylamines, and two cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles, with or without colipids, and therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, polypeptides and low molecular weight organic compounds. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells.